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Atrial fibrillation (AF) is not uncommon in the elderly. 
In the Framingham Heart Study, the lifetime risk of 
this arrhythmia from the age of 55 years onwards has 
recently been estimated to be as high as 37% 1. This 
percentage is remarkably higher than the one cal-
culated from the same cohort a decade ago  2, likely 
because of a reduction in mortality from competing 
diseases and intensified medical surveillance, both in 
general and specifically for AF, as a consequence of 
increased awareness of this condition.
The most fearsome presentation of AF is systemic 
embolism and especially ischemic stroke, which be-
comes particularly threatening at older ages due to 
higher mortality and probability of long-term seque-
lae, with functional impairment and ensuing dramatic 
health care and social costs 3. The proportion of AF-
related strokes among any ischemic stroke is around 
10% 4 5 and there is a strong correlation between AF 
underlying a cerebrovascular event and age or the 
CHA2DS2-VASc score, which is used to quantify the 
risk of AF-associated stroke or transient ischemic at-
tack and includes age. 
Thus, the elder is prone to AF and its potentially devas-
tating complications. This is a first reason why advocat-
ing the search of AF in asymptomatic individuals who 
are older than a certain threshold age. Second and fun-
damental, a therapy is available that consistently and 
noticeably diminishes the risk of cardioembolic cerebral 
events secondary to AF, and thus provides a strong 
rationale to screen apparently unaffected subjects for 
the arrhythmia. Oral anticoagulation (OAC) are highly 
effective in preventing AF-related stroke, and the new 
generation of direct OAC (DOAC) is also characterized 
by more stable pharmacokinetics and more favorable 
safety profile as compared with vitamin K antagonists 6. 
Moreover, these benefits persist among the old and the 
very old 7. To give a measure of the impact of OAC treat-
ment on AF outcomes, in England from 2011 to 2016 
a 1% increase in OAC use was associated with a 0.8% 
decrease in the weekly rate of AF-related stroke, while 
4068 more strokes would have occurred in 2015/2016 
if the use of OAC had remained at 2009 levels 8.
Based on these considerations, screening programs 
for silent AF have been intensively studied.
Any screening strategy must be low-risk and low-
cost to be implemented community-wide. Single-time 
point or repeated electrocardiography (ECG) may 
meet these requirements and, thereby, has been pro-
posed to screen for unrecognized AF. Technological 
advances have led to handheld devices with verifiable 
ECG traces, which combine accuracy and simplicity 
of use, rendering the prospect of AF screening even 
more appealing. For instance, participants in the 
recent REHEARSE-AF study  9 were provided with a 
monitor attached to a WiFi-enabled iPod to acquire 
30-second single-lead ECGs twice weekly or when 
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symptomatic over 12 months and transmit the record-
ings to a secure server. In the STROKESTOP study 10, 
ECG were obtained intermittently over two weeks by 
means of an integrated mobile transmitter, which was 
activated by placing their thumbs on the device and 
sent 30-second ECG strip data to a database. 
Since the prevalence of AF increases with age, ap-
plying these tools to older subjects will make the per-
centage of cases in which the screening identify AF 
closer to the total number of positive tests (i.e., the 
positive predictive value will be higher). Keeping the 
example of the STROKESTOP study, which recruited 
75-76-year-old persons, previously unknown AF was 
found in 3% of the participants, with 0.5% being di-
agnosed with AF on the first ECG. By using the same 
technology with persons in the same age range, but 
≥ 2 points at the CHADS2 score, AF was discovered 
in 7.4%  11. In REHEARSE-AF, a CHADS-VASc score 
of ≥  4 was the strongest predictor of incident AF  9. 
Against this background, there has been enthusiasm 
for AF screening, both in the scientific community and 
in the lay literature. However, many questions are still 
open. Is there any harm of systematic screening for 
AF with ECG? Does it affect health outcomes, such 
as all-cause mortality and stroke morbidity and mor-
tality? Which are the benefits and harms of OAC for 
screen-detected AF? (antiplatelet therapy is not rec-
ommended for the prevention of AF-related stroke) 12.
These questions have been addressed by a recent sys-
tematic review, carried out to inform the US Preventive 
Service Task Force and specifically focused on studies 
that enrolled adults of 65 years of age or older without 
a history of stroke, transient ischemic attack, coronary 
heart disease or heart failure 13. In spite of an extensive 
work of data extraction and analysis, however, the au-
thors could provide almost no definite answer. In fact, 
the only firm conclusion they reached is that systemat-
ic or opportunistic screening of unselected or explicitly 
asymptomatic adults with ECG leads to the detection 
of more cases of AF, as compared with no screening. 
At sharp odds with the promising results of the studies 
of AF screening individually considered, the effects of 
ECG screening cannot be precisely gauged. Impor-
tantly, this is the case with the risk/benefit ratio of OAC 
prompted by detection of unknown AF, but also with 
other aspects that are often overlooked but are actu-
ally extremely relevant in evaluating the feasibility of 
a screening approach, such as anxiety generated by 
testing or cost-effectiveness. 
Inevitably and laconically, the accompanying recom-
mendation statement by the US Preventive Services 
Task Force concluded that “the current evidence is in-
sufficient to assess the balance of benefits and harms 
of screening for atrial fibrillation with ECG” 14. 
The jury is still out.
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